MRX34: Phase I discontinued

Mirna voluntarily terminated an open-label, dose-escalation, dose-expansion, U.S. and Korean Phase I trial of IV MRX34 after a fifth, immune-related

Read the full 209 word article

How to gain access

Continue reading with a
two-week free trial.